Literature DB >> 15115761

The structure of the tau haplotype in controls and in progressive supranuclear palsy.

Alan M Pittman1, Amanda J Myers, Jaime Duckworth, Leslie Bryden, Melissa Hanson, Patrick Abou-Sleiman, Nicholas W Wood, John Hardy, Andrew Lees, Rohan de Silva.   

Abstract

The group of neurodegenerative diseases collectively known as tauopathies are characterized by hallmark lesions consisting of fibrillar aggregates of the microtubule-associated protein, tau (MAPT). Mutations of the tau gene (MAPT) are the cause of frontotemporal dementia with parkinsonism linked to chromosome 17, giving tau a central role in the pathogenic process. The chromosomal region containing MAPT has been shown to evolve into two major haplotypes, H1 and H2, which are defined by linkage disequilibrium (LD) between several polymorphisms over the entire MAPT gene. Studies to date suggest a complete absence of recombination between these two haplotypes. The more common haplotype H1 is over-represented in patients with progressive supranuclear palsy (PSP) and corticobasal degeneration. Using single nucleotide polymorphisms, we mapped LD in the regions flanking MAPT and have established the maximum extent of the haplotype block on chromosome 17q21.31 as a region covering approximately 2 Mb. This gene-rich region extends centromerically beyond the corticotrophin releasing hormone receptor 1 gene (CRHR1) to a region of approximately 400 kb, where there is a complete loss of LD. The telomeric end is defined by an approximately 150 kb region just beyond the WNT3 gene. We show that the entire, fully extended H1 haplotype is associated with PSP, which implicates several other genes in addition to MAPT, as candidate pathogenic loci.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115761     DOI: 10.1093/hmg/ddh138

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  47 in total

Review 1.  Biomarkers to identify the pathological basis for frontotemporal lobar degeneration.

Authors:  Murray Grossman
Journal:  J Mol Neurosci       Date:  2011-07-22       Impact factor: 3.444

Review 2.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

3.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

4.  Genome-wide association study identifies MAPT locus influencing human plasma tau levels.

Authors:  Jason Chen; Jin-Tai Yu; Kevin Wojta; Hui-Fu Wang; Henrik Zetterberg; Kaj Blennow; Jennifer S Yokoyama; Michael W Weiner; Joel H Kramer; Howard Rosen; Bruce L Miller; Giovanni Coppola; Adam L Boxer
Journal:  Neurology       Date:  2017-01-18       Impact factor: 9.910

5.  Evidence for dysregulation of genome-wide recombination in oocytes with nondisjoined chromosomes 21.

Authors:  Candace D Middlebrooks; Nandita Mukhopadhyay; Stuart W Tinker; Emily Graves Allen; Lora J H Bean; Ferdouse Begum; Reshmi Chowdhury; Vivian Cheung; Kimberly Doheny; Marcia Adams; Eleanor Feingold; Stephanie L Sherman
Journal:  Hum Mol Genet       Date:  2013-09-06       Impact factor: 6.150

6.  Biomarkers in the primary progressive aphasias.

Authors:  Murray Grossman
Journal:  Aphasiology       Date:  2014-09       Impact factor: 2.773

7.  H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers.

Authors:  Elisa Canu; Marina Boccardi; Roberta Ghidoni; Luisa Benussi; Cristina Testa; Michela Pievani; Matteo Bonetti; Giuliano Binetti; Giovanni B Frisoni
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

8.  Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons.

Authors:  Pier Paolo Peruzzi; Sean E Lawler; Steve L Senior; Nina Dmitrieva; Pauline A H Edser; Davide Gianni; E Antonio Chiocca; Richard Wade-Martins
Journal:  Mol Ther       Date:  2009-04-07       Impact factor: 11.454

9.  Tau isoform regulation is region- and cell-specific in mouse brain.

Authors:  Pamela McMillan; Elena Korvatska; Parvoneh Poorkaj; Zana Evstafjeva; Linda Robinson; Lynne Greenup; James Leverenz; Gerard D Schellenberg; Ian D'Souza
Journal:  J Comp Neurol       Date:  2008-12-20       Impact factor: 3.215

Review 10.  Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.

Authors:  Jianhua Zhou; Qingming Yu; Tie Zou
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.